Insider · CIK 0001916940

Marks Gilbert Lynn

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001916940

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-12	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+2,283 sh	—	—	84,156
2026-07-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+2,789 sh	—	—	81,873
2026-04-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+3,775 sh	—	—	79,084
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.7K sh	—	—	10,665
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.7K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,362
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−23.7K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.4K sh	—	—	20,400
2026-01-12	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+11.6K sh	—	—	75,309
2025-10-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+10.4K sh	—	—	63,749
2025-07-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+11.9K sh	—	—	53,382
2025-05-22	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.1K sh	—	—	19,111
2025-04-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+9,705 sh	—	—	41,507
2024-12-19	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+8,972 sh	—	—	31,802
2024-06-19	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+64.5K sh	—	—	64,503
2023-06-07	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,362

Recent filings

Accepted (ET)
Oct 134
Marks Gilbert Lynn0001193125-26-420643
SEC(opens sec.gov)
Jul 104
Marks Gilbert Lynn0001193125-26-301166
SEC(opens sec.gov)
Apr 104
Marks Gilbert Lynn0001193125-26-151628
SEC(opens sec.gov)
Mar 234
Marks Gilbert Lynn0001193125-26-120230
SEC(opens sec.gov)
Feb 234
Marks Gilbert Lynn0001193125-26-064105
SEC(opens sec.gov)
Jan 144
Marks Gilbert Lynn0001193125-26-013035
SEC(opens sec.gov)
Oct 144
Marks Gilbert Lynn0001193125-25-238984
SEC(opens sec.gov)
Jul 114
Marks Gilbert Lynn0000950170-25-095406
SEC(opens sec.gov)
May 234
Marks Gilbert Lynn0000950170-25-077036
SEC(opens sec.gov)
Apr 114
Marks Gilbert Lynn0000950170-25-053348
SEC(opens sec.gov)
Dec 234
Marks Gilbert Lynn0000950170-24-139797
SEC(opens sec.gov)
Jun 214
Marks Gilbert Lynn0000950170-24-076408
SEC(opens sec.gov)
Jun 94
Marks Gilbert Lynn0000899243-23-015314
SEC(opens sec.gov)
May 164
Marks Gilbert Lynn0000899243-22-018272
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.DirectorANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025